as 10-07-2025 1:19pm EST
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies.
Founded: | 2020 | Country: | United States |
Employees: | N/A | City: | LAKEWAY |
Market Cap: | 98.6M | IPO Year: | 2021 |
Target Price: | $8.00 | AVG Volume (30 days): | 124.0K |
Analyst Decision: | Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.25 | EPS Growth: | N/A |
52 Week Low/High: | $0.80 - $3.42 | Next Earning Date: | 11-12-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
ANEB Breaking Stock News: Dive into ANEB Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Business Wire
5 months ago
Simply Wall St.
5 months ago
Business Wire
8 months ago
Simply Wall St.
8 months ago
Simply Wall St.
9 months ago
TipRanks
9 months ago
Business Wire
9 months ago
The information presented on this page, "ANEB Anebulo Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.